Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899620 | 0.83 | SMYD3 (0.54) | SMYD3 | |
| SCHEMBL23143521 | 0.83 | SMYD3 (0.54) | SMYD3 | |
| SCHEMBL29528307 | 0.80 | SMYD3 (0.59) | HDAC6SMYD3HDAC3HDAC1CRBN | |
| SCHEMBL23143550 | 0.79 | SMYD3 (0.72) | SMYD3CRBN | |
| SCHEMBL29899597 | 0.79 | SMYD3 (0.72) | SMYD3CRBN | |
| SCHEMBL24973 | 0.78 | SMYD3 (0.58) | HDAC2HDAC8HDAC6SMYD3HDAC3 | |
| SCHEMBL3183636 | 0.77 | SMYD3 (0.60) | SMYD3 | |
| SCHEMBL5316057 | 0.76 | CRBN (0.81) | HDAC6SMYD3HDAC3HDAC1CRBN | |
| SCHEMBL3193145 | 0.75 | SMYD3 (0.71) | HDAC2HDAC8HDAC6SMYD3HDAC3 | |
| SCHEMBL3190640 | 0.75 | RAB9A (0.61) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542274-B1 | Therapeutic compounds and methods of use thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2023-01-03 | — | — | US | disclosed |
| US-20210147441-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2021-05-20 | — | — | US | disclosed |
| WO-2021061053-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147441-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | UBQLN2, TXNRD1, TXNRD2 | HDAC2 2017/4885HDAC8 2207/4885HDAC6 120/4885 |
| US-11542274-B1 | Therapeutic compounds and methods of use thereof | MDM2, SUMO2, XIAP | HDAC2 1725/4885HDAC8 2269/4885HDAC6 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.